Combined chemotherapy and endoscopic ultrasound-guided intratumoral 32P implantation for locally advanced pancreatic adenocarcinoma: a pilot study.
Endoscopy
; 54(1): 75-80, 2022 01.
Article
em En
| MEDLINE
| ID: mdl-33440437
ABSTRACT
BACKGROUND:
This study evaluated clinical outcomes of combined chemotherapy and endoscopic ultrasound (EUS)-guided intratumoral radioactive phosphorus-32 (32P) implantation in locally advanced pancreatic adenocarcinoma (LAPC).METHODS:
Consecutive patients with newly diagnosed LAPC were recruited over 20 months. Baseline computed tomography and 18F-2-fluoro-2-deoxy-D-glucose (18FDG) positron emission tomography-computed tomography were performed and repeated after 12 weeks to assess treatment response. Following two cycles of conventional chemotherapy, patients underwent EUS-guided 32P implantation followed by six chemotherapy cycles.RESULTS:
12 patients with LAPC (median age 69 years [interquartile range 61.5-73.3]; 8 male) completed treatment. Technical success was 100â% with no procedural complications. At 12 weeks, median reduction in tumor volume was 8.2âcm3 (95â% confidence interval 4.95-10.85; Pâ=â0.003), with minimal or no 18FDG uptake in nine patients (75â%). Tumor downstaging was achieved in six patients (50â%), leading to successful resection in five (42â%), including four R0 resections (80â%).CONCLUSIONS:
EUS-guided 32P implantation was feasible, well tolerated, and resulted in a 42â% surgical resection rate. Further evaluation in a larger randomized multicenter trial is warranted.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Pancreáticas
/
Adenocarcinoma
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article